★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Bio-Rad Laboratories, Inc. (BIO) Moat Analysis
Bio-Rad Laboratories, Inc.
BIO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Bio-Rad operates Life Science and Clinical Diagnostics. Q2 2026 sales were $651.0M and fell 1.9% in currency-neutral terms: Life Science declined 5.1%, while Clinical Diagnostics rose 0.3%. Life Science has accumulated technical know-how, but its patent count and direct sales force do not establish an exclusive IP or distribution choke point; the distribution moat is therefore removed and the know-how rating reduced. Clinical Diagnostics has the stronger moat: installed systems generate recurring kits and reagents, and laboratories standardize workflows around supplier platforms, creating validation and operating switching costs. The company reaffirmed a wide full-year currency-neutral growth range of -3.0% to +0.5%, underscoring weak near-term demand. Platform replacement cycles, tenders, reimbursement pressure, research funding, tariffs, geopolitical disruption and larger competitors remain the main risks.
Primary segment
Clinical Diagnostics
Market structure
Oligopoly
Market share
9%-10% (implied)
HHI: —
Coverage
2 segments · 6 tags
Updated 2026-08-23
Segments
Life Science
Life science research tools, instruments, reagents, and consumables
Revenue
38.7%
Structure
Competitive
Pricing
moderate
Share
5%-6% (implied)
Peers
Clinical Diagnostics
In vitro diagnostics test systems, reagents/test kits, informatics, and clinical laboratory quality controls
Revenue
61.3%
Structure
Oligopoly
Pricing
moderate
Share
9%-10% (implied)
Peers
Moat Claims
Life Science
Life science research tools, instruments, reagents, and consumables
Revenue_share uses Q2 2026 segment net sales: Life Science $252.0M of $651.0M total. Operating_profit_share is a proxy using Q2 segment gross profit of $143.5M of $345.8M because gross profit is Bio-Rad's CODM segment profit measure. The former distribution-control moat was removed: a direct specialist sales force supports execution but does not establish channel control against larger peers.
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Product development and manufacturing rely on accumulated scientific know-how, but Bio-Rad does not identify an exclusive IP choke point and larger peers can fund competing platforms.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Technology shifts (new modalities) making legacy expertise less relevant
- IP challenges/circumvention by competitors
- Talent attrition in key scientific/engineering roles
Leading indicators
- R&D efficiency (new product revenue contribution)
- Patent litigation outcomes / freedom-to-operate issues
- Time-to-market vs peers in new modalities
Counterarguments
- Patents are not necessarily decisive; innovation cycles can outpace IP
- Well-capitalized rivals can invest to catch up in core workflows
Clinical Diagnostics
In vitro diagnostics test systems, reagents/test kits, informatics, and clinical laboratory quality controls
Revenue_share uses Q2 2026 segment net sales: Clinical Diagnostics $399.0M of $651.0M total. Operating_profit_share is a proxy using Q2 segment gross profit of $202.3M of $345.8M because gross profit is Bio-Rad's CODM segment profit measure.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Installed systems drive recurring revenue through repeat purchase of test kits, reagents, consumables, and specialized quality controls.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Competitive displacement of installed systems at replacement cycles
- Price pressure from group purchasing organizations and tenders
- Reimbursement changes compressing lab budgets
Leading indicators
- Recurring reagent/kit revenue retention (if disclosed)
- Installed base growth / placements
- Clinical Diagnostics gross margin trend
Counterarguments
- Large IVD competitors can bundle broader menus and win platform tenders
- Labs can consolidate vendors for cost reasons, reducing stickiness
Switching Costs General
Demand
Switching Costs General
Strength
Durability
Confidence
Evidence
Labs standardize methodologies around specific systems; switching vendors can require workflow changes, validation, training, and operational disruption.
Switching Costs General moat: definition, examples, and stocks
Erosion risks
- Standardization shifts toward multi-vendor interoperability
- Competitors offer switching incentives and bundled pricing
- Regulatory changes enabling easier substitution
Leading indicators
- Competitive win/loss rates in platform replacements
- Customer churn signals (service contract losses, consumables declines)
- Menu expansion vs competitors in targeted niches
Counterarguments
- Switching can be feasible during major refresh cycles
- Large labs may have sophisticated validation teams and can multi-source
Evidence
We own over 2,100 U.S. and international patents and numerous trademarks.
Scale of IP portfolio supports a know-how + IP barrier, though not necessarily a single choke point.
our ability to develop and manufacture our products depends primarily on our knowledge, technology and special skills
Company frames defensibility as rooted in expertise and execution (not just patents).
Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%.
Shows current product-level traction, while the 5.1% currency-neutral segment decline is counterevidence against a broad or strengthening advantage.
We estimate that the worldwide sales in the markets we serve are approximately $19 billion.
Management estimate of total sales in the markets served by the Life Science segment.
Net sales 2025 $1,021.1 $1,562.1 $,
Life Science FY2025 net sales (in millions) used as the numerator.
Showing 5 of 9 sources.
Risks & Indicators
Erosion risks
- Technology shifts (new modalities) making legacy expertise less relevant
- IP challenges/circumvention by competitors
- Talent attrition in key scientific/engineering roles
- Competitive displacement of installed systems at replacement cycles
- Price pressure from group purchasing organizations and tenders
- Reimbursement changes compressing lab budgets
Leading indicators
- R&D efficiency (new product revenue contribution)
- Patent litigation outcomes / freedom-to-operate issues
- Time-to-market vs peers in new modalities
- Recurring reagent/kit revenue retention (if disclosed)
- Installed base growth / placements
- Clinical Diagnostics gross margin trend
Research BIO elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.